Earnings summaries and quarterly performance for GeoVax Labs.
Executive leadership at GeoVax Labs.
Board of directors at GeoVax Labs.
Research analysts who have asked questions during GeoVax Labs earnings calls.
James Molloy
Alliance Global Partners
2 questions for GOVX
Also covers: ABEO, ACXP, AIM +11 more
Jeffrey Kraws
Crystal Research Associates
2 questions for GOVX
Jonathan Aschoff
B. Riley Securities
2 questions for GOVX
Also covers: BFRI, BPTH, BRTX +6 more
Robert LeBoyer
NOBLE Capital Markets
2 questions for GOVX
Also covers: OCGN, PDSB, TOI
John Vandermosten
Zacks Small Cap Research
1 question for GOVX
Also covers: ACHV, BIOR, BLRX +10 more
Laura Suriel
Alliance Global Partners
1 question for GOVX
Also covers: BCDA, IMNN, INMB
Vernon Bernardino
H.C. Wainwright & Co.
1 question for GOVX
Also covers: CANF, ELDN, GALT +6 more
Recent press releases and 8-K filings for GOVX.
GeoVax Labs, Inc. Reports Q3 2025 Financial Results and Business Updates
GOVX
Earnings
New Projects/Investments
- GeoVax Labs, Inc. reported a net loss of $6,318,914, or $0.31 per share, for the three-month period ended September 30, 2025. For the nine-month period ended September 30, 2025, the net loss was $17,046,348, or $0.97 per share.
- The company recorded $0 in revenue for Q3 2025, compared to $2,789,484 in the comparable period of 2024, primarily due to the termination of the BARDA/RRPV contract in April 2025.
- Research and development expenses decreased to $5,043,504 for Q3 2025 from $7,402,884 in Q3 2024, mainly due to discontinued costs associated with the BARDA/RRPV contract termination and lower costs for GEO-CM04S1 clinical trials.
- GeoVax is accelerating development of its GEO-MVA vaccine for Mpox/Smallpox, with favorable scientific advice from the European Medicines Agency (EMA) supporting a streamlined regulatory pathway.
- The GEO-CM04S1 COVID-19 vaccine program showed strong immunogenicity data in immunocompromised patients, including those with Chronic Lymphocytic Leukemia (CLL) and hematologic cancers, achieving its primary immunogenicity endpoint in the CLL trial.
Nov 13, 2025, 10:20 PM
GeoVax Reports Q3 2025 Financials and Expedited GEO-MVA Development Path
GOVX
Earnings
New Projects/Investments
- GeoVax reported $2.5 million in revenues for the nine months ended September 30, 2025, with no contract revenues in Q3 2025 following the termination of the BARDA Project NextGen contract.
- The company posted a net loss of $6.3 million for Q3 2025 and $17 million for the nine-month period, with cash balances at $5 million as of September 30, 2025.
- The European Medicines Agency (EMA) provided expedited development path guidance for GEO-MVA, GeoVax's mpox and smallpox vaccine candidate, allowing direct progression to a Phase III immunobridging trial.
- GeoVax is advancing clinical studies for GEO-CM04S1 in immunocompromised patients and progressing plans for a Phase II Gadeptin trial in head and neck cancer, while exploring strategic partnerships, non-dilutive funding, or additional common stock offerings to support its programs.
Nov 13, 2025, 9:30 PM
GeoVax Labs Announces $2.5 Million Registered Direct Offering
GOVX
New Projects/Investments
- GeoVax Labs, Inc. announced a registered direct offering with certain healthcare-focused institutional investors on September 30, 2025.
- The offering involves the sale of 3,968,256 shares of common stock (or equivalents) and warrants to purchase up to 11,904,768 shares of common stock at a combined purchase price of $0.63 per share and accompanying warrant.
- The gross proceeds from the offering are expected to be approximately $2.5 million, with net proceeds of approximately $2,325,000 after deducting fees and expenses.
- The company intends to use the net proceeds to advance its product candidates, including research and development, manufacturing, clinical studies, and working capital.
- The warrants will have an exercise price of $0.63 per share, will be exercisable upon shareholder approval, and will expire 5 years from shareholder approval.
Sep 30, 2025, 8:43 PM
GeoVax Labs Provides Update on Vaccine Development and Funding Plans
GOVX
New Projects/Investments
Guidance Update
M&A
- GeoVax Labs is advancing its GEO-CM04S1 vaccine for immunocompromised COVID-19 patients, with clinical trial results showing its vaccine's immune response exceeds mRNA vaccines; notably, the Pfizer arm of a chronic lymphocytic leukemia (CLL) trial was halted as it did not meet desired endpoints, while GeoVax's vaccine exceeded them.
- The company plans to raise an additional $12 million to $15 million by the end of 2025 to support the progress of its programs, which also include an mpox/smallpox vaccine and solid tumor therapy.
- GeoVax is actively communicating with the investment community to address perceived undervaluation, with some analysts suggesting a stock price of $5 to $12 per share.
Sep 25, 2025, 7:55 PM
Quarterly earnings call transcripts for GeoVax Labs.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more